{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    35,
    36,
    37,
    38,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Ibrutinib",
        "type": {
          "id": "b453fff7-5710-4e19-b8dd-d5eab81c5ef3",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "3e8c9c3b-b3d4-4766-8e90-e99f41db0d1f",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK).",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "fa27eb96-4727-427a-82cf-4cfb24df12f5",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "dd3752e4-2998-4871-813b-a6d36cd68ef0",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for ibrutinib.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "Bendamustine hydrochloride",
        "type": {
          "id": "835c821d-51d7-46fd-bc43-a5c5d1c5c152",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "f7de75d1-511a-4b86-9c2f-e8e6a701dcc6",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen).",
        "productIds": [
          "prod_3"
        ],
        "administrationIds": [
          "admin_3"
        ]
      },
      {
        "id": "int_4",
        "name": "Rituximab",
        "type": {
          "id": "833340b8-8c4e-4de8-8fcd-f9bd01ad33b8",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "f5d923d7-4436-47b5-950b-395531dee707",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases.",
        "administrationIds": [
          "admin_4"
        ]
      },
      {
        "id": "int_5",
        "name": "Antimicrobial prophylaxis",
        "type": {
          "id": "2ac5f9d8-1c52-451e-b28c-afe388ce9108",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "27c616f3-5f15-4bb6-87f5-8415bd3cdc47",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections.",
        "administrationIds": [
          "admin_5"
        ]
      },
      {
        "id": "int_6",
        "name": "Anti-hormonal therapy",
        "type": {
          "id": "adb74912-5073-4731-8539-9ed5eeae0ad4",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "8d7e5278-e493-41a5-89f7-2335a3b817b1",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "id": "int_7",
        "name": "Warfarin",
        "type": {
          "id": "cc6ab9c9-78e5-4f14-a8d5-175e5dfba368",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "95c47e19-ebb8-44bb-b693-312fd9b5df55",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "id": "int_8",
        "name": "Fish oil and Vitamin E",
        "type": {
          "id": "3eb96b92-a5e5-49fa-84eb-db85d0759033",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "f6c7b734-4ff2-4512-b0f1-f18f6245b10c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "id": "int_9",
        "name": "Strong or moderate CYP3A inhibitors",
        "type": {
          "id": "f0d093ef-4861-4427-ae97-3bd3c371948c",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "16df579b-42f3-426f-a38a-dad98eb7ab05",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Ibrutinib capsules",
        "administrableDoseForm": {
          "id": "1c1da2f6-9ed2-45fc-8b76-07a1cd9de066",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "acbb0339-3eff-4c61-8ecf-9c498351b6fa",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "a3b975b7-6b48-4f2d-b70a-3305568ed27c",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "140 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "id": "prod_2",
        "name": "Bendamustine hydrochloride",
        "administrableDoseForm": {
          "id": "29fc6df3-d254-484a-b053-21e813cfc680",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "3aa89d94-6e9e-4cfb-a83c-0c38a882edb6",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "9c491387-80e0-402f-8d13-fe191593b411",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_2"
        ],
        "manufacturer": "Not specified"
      },
      {
        "id": "prod_3",
        "name": "Rituximab",
        "administrableDoseForm": {
          "id": "bd15e9fc-65b1-4ff8-a3ed-0733521a2ec5",
          "code": "C42945",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Injection",
          "standardCode": {
            "id": "7a944737-5387-4258-9c24-b10b2604bd77",
            "code": "C42945",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Injection",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "689d48ea-0623-4932-b1bf-d8277ff28b45",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "Not specified",
        "substanceIds": [
          "sub_3"
        ],
        "manufacturer": "Not specified"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Ibrutinib 560 mg daily",
        "instanceType": "Administration",
        "dose": "560 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "id": "admin_2",
        "name": "Bendamustine 90 mg/m2",
        "instanceType": "Administration",
        "dose": "90 mg/m2",
        "doseFrequency": "Days 1 and 2 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 6 cycles"
      },
      {
        "id": "admin_3",
        "name": "Rituximab Induction",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of each 28-day cycle",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Cycles 1 to 6"
      },
      {
        "id": "admin_4",
        "name": "Rituximab Maintenance",
        "instanceType": "Administration",
        "dose": "375 mg/m2",
        "doseFrequency": "Day 1 of every second cycle (even cycles)",
        "route": {
          "code": "Intravenous",
          "codeSystem": "USDM",
          "decode": "Intravenous"
        },
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "id": "admin_5",
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "instanceType": "Administration",
        "dose": "140 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Ibrutinib",
        "instanceType": "Substance",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "id": "sub_2",
        "name": "Bendamustine hydrochloride",
        "instanceType": "Substance",
        "description": "Mechlorethamine derivative"
      },
      {
        "id": "sub_3",
        "name": "Rituximab",
        "instanceType": "Substance",
        "description": "Monoclonal antibody"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 9,
      "productCount": 3,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Ibrutinib",
        "role": "Investigational Product",
        "description": "First-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton’s tyrosine kinase (BTK)."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for ibrutinib."
      },
      {
        "name": "Bendamustine hydrochloride",
        "role": "Background Therapy",
        "description": "Antineoplastic alkylating agent used in combination with rituximab (BR regimen)."
      },
      {
        "name": "Rituximab",
        "role": "Background Therapy",
        "description": "CD20-directed cytolytic antibody used in induction and maintenance phases."
      },
      {
        "name": "Antimicrobial prophylaxis",
        "role": "Concomitant Medication",
        "description": "Permitted and should be considered for subjects at increased risk for opportunistic infections."
      },
      {
        "name": "Anti-hormonal therapy",
        "role": "Concomitant Medication",
        "description": "Permitted after discussion with the sponsor’s medical monitor."
      },
      {
        "name": "Warfarin",
        "role": "Concomitant Medication",
        "description": "Prohibited; other vitamin K antagonists are also prohibited."
      },
      {
        "name": "Fish oil and Vitamin E",
        "role": "Concomitant Medication",
        "description": "Supplements that should be avoided due to bleeding risk."
      },
      {
        "name": "Strong or moderate CYP3A inhibitors",
        "role": "Concomitant Medication",
        "description": "Should be avoided; if required, ibrutinib dose must be reduced or withheld."
      }
    ],
    "products": [
      {
        "name": "Ibrutinib capsules",
        "doseForm": "Capsule",
        "strength": "140 mg",
        "manufacturer": "Janssen Research & Development / Pharmacyclics LLC"
      },
      {
        "name": "Bendamustine hydrochloride",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      },
      {
        "name": "Rituximab",
        "doseForm": "Injection",
        "strength": "Not specified",
        "manufacturer": "Not specified"
      }
    ],
    "substances": [
      {
        "name": "Ibrutinib",
        "description": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one"
      },
      {
        "name": "Bendamustine hydrochloride",
        "description": "Mechlorethamine derivative"
      },
      {
        "name": "Rituximab",
        "description": "Monoclonal antibody"
      }
    ],
    "administrations": [
      {
        "name": "Ibrutinib 560 mg daily",
        "dose": "560 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Daily and continuously until disease progression or unacceptable toxicity"
      },
      {
        "name": "Bendamustine 90 mg/m2",
        "dose": "90 mg/m2",
        "frequency": "Days 1 and 2 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Maximum of 6 cycles"
      },
      {
        "name": "Rituximab Induction",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of each 28-day cycle",
        "route": "Intravenous",
        "duration": "Cycles 1 to 6"
      },
      {
        "name": "Rituximab Maintenance",
        "dose": "375 mg/m2",
        "frequency": "Day 1 of every second cycle (even cycles)",
        "route": "Intravenous",
        "duration": "Maximum of 12 additional doses (up to Cycle 30)"
      },
      {
        "name": "Ibrutinib Dose Reduction (Strong CYP3A Inhibitor)",
        "dose": "140 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Duration of strong CYP3A inhibitor use"
      }
    ],
    "devices": []
  }
}